Rituximab for severe immune checkpoint inhibitor-related adverse events: a multicenter case series
Rituximab appears to be an effective therapeutic option for selected severe ICI-related irAEs, particularly when conventional immunosuppressive regimens fail. These real-world data highlight the potential role of B-cell-targeted therapy in the management of complex irAEs and support further evaluation in prospective studies.
Authors
- Guillaume Padern
- Elodie Castille
- A. Lamoureux
- Philine Witkowski Durand Viel
- Benjamin Jauzelon
- X. Quantin
- Cyrille Coustal
- A. Maria
- Quentin Dominique Thomas
- Axelle Wauthier
- Steven Marmain
- Stéphanie Hermabessiere
Institutions
- Université de Montpellier (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Clinique Clémentville (FR)
- Institut de Recherche en Cancérologie de Montpellier (FR)
- Hôpital Saint Eloi (FR)
- Université de Nîmes (FR)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1007/s00262-026-04325-y
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00